Cargando…

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

BACKGROUND: Programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) inhibitors have quickly become standard of care for patients with advanced non-small cell lung cancer and increasing numbers of other cancer types. In this report, we discuss the clinical history, pathological evaluation, and genomi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hong, Ma, Weijie, Yoneda, Ken Y., Moore, Elizabeth H., Zhang, Yanhong, Pu, Lee L. Q., Frampton, Garrett M., Molmen, Michael, Stephens, Philip J., Li, Tianhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331657/ https://www.ncbi.nlm.nih.gov/pubmed/28245875 http://dx.doi.org/10.1186/s13045-017-0433-z

Ejemplares similares

Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis
por: Schneider, Thomas-Michael, et al.
Publicado: (2017)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review
por: Huang, Gang, et al.
Publicado: (2020)

Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer
por: Kasi, Arbab Furquan Ud din, et al.
Publicado: (2023)

Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin
por: Yohannan, Binoy, et al.
Publicado: (2022)

Clonal expansion of CD8(+) T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI
por: Schultze-Florey, Christian R., et al.
Publicado: (2021)

An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis
por: Vansteenkiste, Johan
Publicado: (2017)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report
por: Mendiola, Vincent Louie, et al.
Publicado: (2019)

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
por: Chen, Alessandra, et al.
Publicado: (2018)

Remission of ulcerative colitis flare-up induced by nivolumab
por: Iwamoto, Maho, et al.
Publicado: (2020)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
por: Gregory, Gareth P., et al.
Publicado: (2019)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
por: Nakamura, Kenji, et al.
Publicado: (2018)

Complete Remission of Bone Metastases in Renal Cell Carcinoma with Nivolumab
por: Vuyyala, Sowjanya, et al.
Publicado: (2019)

Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma
por: Liao, Ji-Ping, et al.
Publicado: (2017)

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights
por: Foukas, Periklis G., et al.
Publicado: (2018)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
por: Koyama, N., et al.
Publicado: (2018)

Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
por: Souza, Ive L., et al.
Publicado: (2020)

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
por: Zhou, Cathy, et al.
Publicado: (2018)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
por: Ide, Maako, et al.
Publicado: (2018)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
por: Wolfe, Zachary, et al.
Publicado: (2022)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance
por: Lian, Zeng-Zhi, et al.
Publicado: (2016)

Refractory hypotension due to Nivolumab-induced adrenal insufficiency
por: Tsukizawa, Yoshiaki, et al.
Publicado: (2018)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
por: Faieta, Antonio, et al.
Publicado: (2021)

Nivolumab in two cases of refractory mycosis fungoides erythroderma
por: Chmielowska, Ewa
Publicado: (2021)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nkniiq497mqlsbsom4hecchvs3